Robert J Scaringe

CEO Robert J Scaringe sells 34,818 RIVN shares at $15.00 via pre-arranged 10b5-1 plan; stock at $16.30, CEO retains 922,286 shares

Robert J Scaringe sold 34,818 shares (34.8K shares) at $15.00 on 2026-05-28 under a pre-arranged 10b5-1 trading plan adopted on 2025-03-14, meaning this transaction was scheduled rather than discretionary. The sale reduced his holdings by 3.6% to 922,286 shares (922.3K shares) post-transaction. Rivian trades at $16.30 currently, 28.2% below its 52-week high of $22.69, with the company unprofitable over its most recent full fiscal year despite $1.4B quarterly revenue. His prior five trades at RIVN show a mixed pattern: four of the five prior sales posted negative 30-day and 90-day returns, with the most recent sale on 2026-02-18 followed by 30-day -11.2% and 90-day -23.2% declines, though the 2025-04-07 sale marked an exception with 90-day +16.2% gains. Given the pre-arranged nature of this transaction, no timing inference is warranted; however, the broader context of negative equity near a 52-week low and the company's unprofitability warrants tracking stock performance in the 30 and 90 days ahead.

Rivian CEO Scaringe sold 34,900 shares at $16.80; stock down -28.1% from 52-week high.

CEO Robert J Scaringe sold 34,900 shares of RIVN at $16.80 on 2026-02-18, reducing his holdings from 1.08M to 1.04M shares (-3.2% reduction). The sale occurs with RIVN trading -28.1% below its 52-week high of $22.45 and -3.1% lower over the past 30 days. Of particular note: the company reported a net loss of $1.2B on $1.6B quarterly revenue, reflecting ongoing unprofitability. Among Scaringe's 5 prior RIVN sales, 3 were well-timed at the 90-day mark (with negative post-sale returns), though his most recent RIVN sell on 2025-11-11 saw the stock decline only -1.0% in 30 days while gaining +13.1% following his 2025-04-07 sale. The cross-ticker track record shows 55.56% well-timed rate on 18 prior sells, but current pricing pressure and sustained losses warrant investor attention to insider positioning at a heavily loss-making company.

CEO Scaringe sold 52,350 shares of RIVN at $16.60 on 2025-11-11 for $868,832.01; stock now down 9.0% from 52-week high.

Scaringe reduced his RIVN holdings by 52,350 shares (-4.0% vs pre-transaction holdings) at $16.60, maintaining a substantial position of 1,246,405 shares post-sale. The stock has appreciated 24.9% over the 30 days and 33.9% over the 90 days prior to this sale, but remains 9.0% below its 52-week high of $18.02. His prior RIVN trades show a mixed timing pattern: 2 of 5 prior same-ticker sells were well-timed (with negative 90d returns), while his cross-ticker track record shows a 52.94% well-timed rate with an average 90d return of -8.6% across 17 prior sells. The company remains unprofitable with net income of $-1,173,000,000.00 on revenue of $1,558,000,000.00 in the latest quarter, despite 12.1% annual revenue growth. This sale occurs against a backdrop of strong recent price appreciation but persistent fundamental losses.

Rivian CEO Scaringe sells 178,572 shares ($2.7M) at $15.29 avg as stock rallies +40.4% in 30 days

Robert J Scaringe, Rivian's Chief Executive Officer, executed 2 separate sales totaling 178,572 shares for $2,731,022.94 at a blended average price of $15.29 on 2025-05-15 and 2025-05-19, reducing his holdings by 10.7% to 1,483,111 shares. The transactions occurred amid a significant recent rally—Rivian's stock has gained +40.4% over the past 30 days and +12.8% over 90 days, now trading at $16.29 (only 10.0% below the 52-week high of $18.11). Scaringe's prior trades at Rivian show mixed near-term outcomes (30-day returns ranging from -21.0% to +13.1%), though 2 of 2 measured 90-day outcomes were negative (-30.7% and -16.4%), suggesting some historical timing discipline at this ticker. Against his cross-ticker track record of a 58.33% well-timed sell rate (90-day declines), the significance of this sale lies in its scale and timing relative to the recent momentum: the CEO is liquidating a meaningful portion of his position after a sharp rally, while the company remains unprofitable (full-year net income: $-545,000,000) despite 12.1% annual revenue growth.

CEO Scaringe sells 71,429 RIVN shares at $11.25; stock down 35.0% from 52-week high, company reporting -$1.1B net loss.

Robert J Scaringe, CEO of Rivian, sold 71,429 shares at $11.25 on 2025-04-07, reducing his holdings by 7.7% to 853,011 shares. This sale occurs as RIVN trades 35.0% below its 52-week high of $18.11 and 4.4% below the transaction price at $11.77 current price, signaling a depressed valuation environment. At the fundamental level, Rivian reported a net loss of -$1.1B against $874.0M in quarterly revenue, reflecting severe profitability challenges despite 12.1% annual revenue growth. Notably, Scaringe's prior three sales at RIVN all proved well-timed at the 90-day mark, with the most recent completed trade (2024-12-23) showing a 90-day return of -16.4%, suggesting his prior exits preceded stock declines. The latest sale adds to a pattern of consistent CEO selling at this ticker and occurs against a backdrop of pronounced operational losses and depressed valuation.

Rivian CEO Scaringe sold 71.4K shares at $11.82 on 2025-03-24; stock -13.8% in 90 days post-recent prior sale

Robert J. Scaringe, CEO of Rivian Automotive, sold 71,429 shares for $844,290.78 at $11.82 per share on 2025-03-24, reducing his holdings by 7.7% from 924,440 to 853,011 shares. This is his second sale in two weeks—he sold again on 2025-03-12 just 12 days prior—amid a stock decline of 13.8% over the past 90 days and a 33.2% retreat from its 52-week high of $18.11. Rivian remains unprofitable with a net loss of $1.1B in its most recent fiscal year, though annual revenue grew 12.1% to $874.0M; the company's $13.7B market cap reflects ongoing investor uncertainty about the path to profitability. At the same-ticker level, Scaringe's prior three measurable 90-day sell outcomes showed 2 of 3 were well-timed (negative 90d returns after the sales), but the frequency and proximity of recent sales warrant monitoring against the backdrop of deteriorating fundamentals and sustained price pressure.

CEO Scaringe sells 71,429 RIVN shares at $11.25; stock now at $10.75, down 40.6% from 52-week high.

Scaringe sold 71,429 shares on 2025-03-12 at $11.25, reducing his holdings by 7.7% to 853,011 shares. The stock has since fallen to $10.75, down 13.9% over the past 30 days and 25.2% over 90 days, currently trading 40.6% below its 52-week high of $18.11. At the same-ticker level, Scaringe's prior five trades at RIVN show a 1-of-3 well-timed rate at the 90-day horizon, with mixed outcomes: his January 2025 sell preceded a 21.0% decline, while his November 2024 sell preceded a 25.0% gain. The company remains unprofitable with a net income of $-1.1B against quarterly revenue of $874.0M, though annual revenue growth stood at 12.1%. The sale occurs within a period of sustained stock weakness and follows a pattern of regular insider selling at this ticker, warranting monitoring of whether subsequent quarters show margin improvement or continued losses.

Rivian CEO Robert Scaringe sold 71,429 shares at $16.17 on 2025-01-06; stock now down 27.4% from 52-week high despite +38.5% rebound in past 90 days.

CEO Robert Scaringe sold 71,429 shares for $1,155,092.64, reducing holdings from 934,790 to 863,361 shares (net -7.6%). The sale price of $16.17 was 13.8% above the current price of $14.21 and within the 52-week range of $8.40–$19.58. At the same-ticker level, Scaringe has made 5 prior trades at RIVN with mixed outcomes: a recent sell on 2024-11-25 showed +25.0% in the following 30 days; earlier sells on 2024-09-23 and 2024-09-12 posted +18.9% and +0.6% at the 90-day mark, indicating his prior RIVN sells were not well-timed (stock rose after). The company remains unprofitable (net income $-1.1B), though revenue grew 167.4% year-over-year, and Scaringe has continued selling throughout late 2024. This transaction occurs in the context of substantial revenue growth but persistent losses and a stock that has recovered 38.5% in 90 days despite remaining 27.4% below its yearly high.

CEO Robert Scaringe sold 71,429 shares of RIVN at $13.88, reducing holdings by -7.6%; stock now +21.6% in 30 days post-sale

CEO Robert Scaringe sold 71,429 shares on 2024-12-23 at $13.88, reducing his RIVN position by -7.6% from 934,790 to 863,361 shares, generating $991,291.66 in proceeds. The stock has since rallied +21.6% over 30 days and +21.0% over 90 days, trading at $14.04 against a 52-week high of $23.73. His prior RIVN sales show a mixed track record: of five measurable same-ticker sales, only one (2024-09-23) was well-timed with a negative 90-day return of +18.9%; three others suffered 90-day declines ranging from -23.2% to -41.0%. Cross-ticker, his sell timing has been poor (50% well-timed rate across 10 prior sells with -14.4% average 90-day return). The company remains unprofitable with a $-1.1B net loss despite $874.0M quarterly revenue and strong +167.4% annual growth, creating fundamental uncertainty beneath recent price appreciation.

CEO Robert Scaringe sold 71,429 shares of RIVN at $13.65 on 2024-12-12; stock now at $15.34

Robert Scaringe, Rivian's Chief Executive Officer, sold 71,429 shares (71.4K shares) at $13.65 on 2024-12-12, reducing his holdings by 7.6% from 934,790 shares to 863,361 shares. The company is unprofitable with a net income of $-1.1B against $874.0M in quarterly revenue, though it posted +167.4% annual revenue growth. This sale occurred as the stock recovered sharply: it has risen +52.5% over the prior 30 days and +17.1% over 90 days from a 52-week low, though it remains -37.0% below its 52-week high of $24.35. At the same ticker (RIVN), Scaringe's prior sales have shown 2 of 3 measurable outcomes with negative 90-day returns, indicating prior trades were well-timed to declines. His cross-ticker track record shows a 57.14% well-timed rate across 9 prior open-market sales, with an average 90-day return of -19.1% after his sells. The current sale follows another sale just 17 days prior on 2024-11-25, establishing a pattern of regular reductions during a period of sustained recovery.